OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
HR+/HER2- Advanced Breast Cancer: Chemotherapy-Free Options For Various Subgroups

HR+/HER2- Advanced Breast Cancer: Chemotherapy-Free Options For Various Subgroups

by Jens Huober | 13 September 2024 | Women's Cancers

A diverse therapeutic landscape is now available for managing HR-positive/HER2-negative advanced breast cancer. A broad spectrum of patients can be covered with targeted approaches in addition to endocrine therapy. The PALOMA-2, MONALEESA-2, and MONARCH 3 studies have...
Early Breast Cancer: New Findings Through Subgroup And Biomarker Analyses

Early Breast Cancer: New Findings Through Subgroup And Biomarker Analyses

by Konstantin Dedes | 5 September 2024 | Women's Cancers

Study data presented at the 2024 ASCO Congress demonstrate that CDK4/6 inhibitors and other therapies are effective in treating early breast cancer within specific subgroups. New biomarker data can also refine treatment algorithms. In patients with hormone receptor...
HER2-Expressing Gynecological Cancers: Catching Up on Targeted Approaches

HER2-Expressing Gynecological Cancers: Catching Up on Targeted Approaches

by Ilaria Colombo | 19 July 2024 | Women's Cancers

Compared to other tumor types, the development of HER2-targeted therapies for gynecological malignancies is lagging somewhat behind. Nevertheless, promising data have already been generated in the treatment of endometrial, cervical, and ovarian cancer.  © Freepik |...
Our New Partnership with Universimed and Leading Opinions

Our New Partnership with Universimed and Leading Opinions

by PEAK Medicals | 17 July 2024 | OncoNews

We are thrilled to announce our new partnership with Universimed, a renowned medical publisher, and their esteemed journal, Leading Opinions. This collaboration marks a significant step forward in our commitment to advancing oncology education.  © OncoViews As part of...
Metastatic Prostate Cancer: Optimization of Systemic Treatment

Metastatic Prostate Cancer: Optimization of Systemic Treatment

by Deborah Mukherji | 3 July 2024 | Urogenital

Clinical trials investigating various drugs in patients with metastatic hormone-sensitive or castration-resistant prostate cancer have revealed significant benefits. While research is ongoing to shed light on issues such as sequencing, treatment de-escalation and...

Recent Posts

  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer
  • Endometrial Cancer: A Revolution That Is Only Just Beginning
  • Advanced Ovarian Cancer: In Search of the Ideal Strategy

Recent Comments

No comments to show.

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}